Elacytarabine Failure Leaves Clavis Scrambling For Buyer
This article was originally published in The Pink Sheet Daily
Executive Summary
The Phase III failure of Clavis’ AML candidate elacytarabine likely spells the end of the road for the Norwegian company and its lipid vector technology approach to drug development. Clavis is aiming to find a buyer or merger option or considering closing its doors.
You may also be interested in...
Clavis/Clovis' Pancreatic Cancer Drug Fails Despite Personalized Medicine Approach
The failure of Clavis Pharma's and Clovis Oncology's novel potential pancreatic cancer therapy CP-4126/CO-101 in the pivotal LEAP trial was associated with the surprising failure of a novel personalized medicine approach to treating the devastating disease.
FDA’s Authority Looks Safe From Judicial Interference Following Supreme Court Abortion Pill Arguments
The agency's and the pharma industry’s worst fears – that a potential ruling in the mifepristone case might usurp the FDA’s scientific authority and throw the stability of the US drug approval process into question – seem unlikely to materialize as the majority of the Supreme Court justices signal the Alliance for Hippocratic Medicine lacks standing to sue.
Bernie Gets Mostly Pharma-Friendly Drug Pricing Results
Changes to inhaler pricing may be more ‘business as usual’ for the drug industry than the Vermont senator wants to let on. FTC, meanwhile, is keeping the patent pressure on Teva, the only inhaler manufacturer to not act following Sanders’ investigation.